MedCap AB (publ) - Asset Resilience Ratio

Latest as of December 2025: 14.21%

MedCap AB (publ) (MCAP) has an Asset Resilience Ratio of 14.21% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check MCAP strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr370.40 Million
≈ $39.86 Million USD Cash + Short-term Investments

Total Assets

Skr2.61 Billion
≈ $280.45 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how MedCap AB (publ)'s Asset Resilience Ratio has changed over time. See MedCap AB (publ) (MCAP) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down MedCap AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MedCap AB (publ) (MCAP) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr370.40 Million 14.21%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr370.40 Million 14.21%

Asset Resilience Insights

  • Moderate Liquidity: MedCap AB (publ) has 14.21% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

MedCap AB (publ) Industry Peers by Asset Resilience Ratio

Compare MedCap AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Medacta Group SA
SW:MOVE
Medical Devices 0.86%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
Xiangyu Medical Co. Ltd. A
SHG:688626
Medical Devices 1.53%
INKON Life Technology Co Ltd
SHE:300143
Medical Devices 5.73%
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%

Annual Asset Resilience Ratio for MedCap AB (publ) (2016–2025)

The table below shows the annual Asset Resilience Ratio data for MedCap AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 14.21% Skr370.40 Million
≈ $39.86 Million
Skr2.61 Billion
≈ $280.45 Million
-4.37pp
2024-12-31 18.58% Skr370.10 Million
≈ $39.83 Million
Skr1.99 Billion
≈ $214.31 Million
+7.26pp
2023-12-31 11.32% Skr188.20 Million
≈ $20.25 Million
Skr1.66 Billion
≈ $178.88 Million
-5.20pp
2022-12-31 16.53% Skr236.20 Million
≈ $25.42 Million
Skr1.43 Billion
≈ $153.82 Million
+4.58pp
2021-12-31 11.95% Skr139.70 Million
≈ $15.03 Million
Skr1.17 Billion
≈ $125.86 Million
-1.60pp
2020-12-31 13.55% Skr146.50 Million
≈ $15.77 Million
Skr1.08 Billion
≈ $116.37 Million
+11.10pp
2019-12-31 2.45% Skr20.60 Million
≈ $2.22 Million
Skr842.30 Million
≈ $90.64 Million
+0.23pp
2018-12-31 2.21% Skr14.80 Million
≈ $1.59 Million
Skr668.90 Million
≈ $71.98 Million
-8.01pp
2017-12-31 10.22% Skr61.33 Million
≈ $6.60 Million
Skr600.20 Million
≈ $64.59 Million
+2.66pp
2016-12-31 7.56% Skr42.59 Million
≈ $4.58 Million
Skr563.16 Million
≈ $60.61 Million
--
pp = percentage points

About MedCap AB (publ)

ST:MCAP Sweden Medical Devices
Market Cap
$771.94 Million
Skr7.17 Billion SEK
Market Cap Rank
#10225 Global
#158 in Sweden
Share Price
Skr477.60
Change (1 day)
-0.62%
52-Week Range
Skr414.00 - Skr670.00
All Time High
Skr670.00
About

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; an… Read more